1

Key performance indicators

of the Roche Group

Economic and business performance

2009 2008 2007

Sales (mCHF) 49,051 45,617 46,133

Research and development (mCHF) 9,874 8,845 8,385
Research and development as % of sales 20.1% 19.4% 18.2%
Operating profit before exceptional items (mCHF) 15,012 13,896 14,468
Operating profit margin 30.6% 30.5% 31.4%
Net financial income (mCHF) –1,668 236 834
Net Income (mCHF) 8,510 10,844 11,437
Core earnings per share (CHF) 12.19 11.04 11.85
Operating free cash flow 15,722 12,378 10,671
Operating free cash flow as % of sales 32.1% 27.1% 23.1%
Net assets (mCHF) 9,414 53,822 53,443
Net cash (debt) (mCHF) –23,867 16,682 17,336
Equity ratio 12.63% 70.70% 68.2%

Increasing value for our shareholders and investors

Dividend per share (CHF) 1) 6.00 5.00 4.60
Dividend (mCHF) 1) 5,175 4,313 3,968
Dividend as % of sales 10.6% 9.5% 8.6%
Payout Ratio 53% 49% 41%
Price of non-voting equity security (Genussschein)
at 31st of December (CHF) 175.80 162.50 195.60
Market capitalization (CHF billions) 151 141 171
Total Shareholder Return (TSR) at 31st of December 12% –16.0% –9.8%
Dow Jones World and FTSE4Good sustainability indexes Leader Included Included

Access to healthcare & patients benefits

Number of major regulatory approvals received 13 14 18
Number of major regulatory filings 23 12 14
Patients actively participating in clinical trials 2) 269,895 235,420 201,752
Patients benefiting from Patient Assistance Programs
(US only) 40,000 38,000 34,480
Number of phase I—III clinical trials at 31st of December 111 119 108
Number of clinical trial protocols (Phase I—IV) published 649 574 480
% of all HIV/AIDS patients living in countries eligible
for no-profit Roche ARV medicines 68% 68% 70%
% of all HIV/AIDS patients living in countries eligible
for reduced-price Roche ARV medicines 83% 83% 86%
Technology Transfer Initiative (TTI) agreements
with companies covering sub-Saharan Africa and the least
developed countries (LDCs) 13 10 9
 2

Commitment to our employees

2009 2008 2007

Number of employees (full-time equivalent — FTE) 81,507 80,080 78,604

Growth in full-time equivalent employees 1,427 1,476 4,232
Total employees’ remuneration (mCHF) 12,080 11,129 10,767
Total employees’ remuneration as % of sales 24.6% 24.4% 23.3%
Percentage of women in total workforce 46% 46% 45%
Percentage of women in management positions 37% 37% 32%
Staff turnover (fluctuation) 7% 9.9% 8.7%
Average number of training hours per employee 26 29 34.5
Numbers of Employees on Roche secondment 4 2 3
Pecentage of eligible employees purchased shares
through Roche CONNECT 37% 36% 36%
Roche’s position in Science magazine’s top employers
in the biotech and pharmaceutical industries 17 th 6 th 18 th
Genentech’s position in Science magazine’s top employers
in the biotech and pharmaceutical industries 1st 1st 2 nd

Commitment to society and the communities we operate in

Income taxes (mCHF) 2870 3,305 3,867
Income taxes as % of sales 5.9% 7.2% 8.4%
Community support by area:
— Humanitarian and social projects 75% 86% 85.5%
— Science and education 17% 11% 11.2%
— Arts and culture 5% 2% 1.8%
— Community and environment 3% 1% 1.5%

Safety, health and environmental protection

Investments in SHE (mCHF) 159 218 215
Operating costs for SHE (mCHF) 294 295 306
Roche Accident Rate 0.074 0.078 0.076
Occupational accidents 392 474 482
Occupational accidents per million working hours 2.92 3.42 3.46
Occupational illnesses 227 270 311
Eco-Efficiency Rate 84.02 77.95 67.19
eco-balance 4.6 4.95 5.15
Total energy consumption (TJ/year) 13,898 13,662 13,664
Total energy consumption (TJ/year per mCHF sales) 0.283 0.299 0.296
Greenhouse gas emissions (tonnes CO 2 equivalents) 1,053,118 1,062,114 1,052,407
Greenhouse gas emissions
(tonnes CO 2 equivalents per mCHF sales) 21.47 23.28 22.81
NO x (t/year) 286 193 169
SO2 (t/year) 9 10 12
Volatile organic compounds (VOCs) (t/year) 177 213 240
Particulate matter (t/year) 27 27 25
Water consumption (million cubic meters per year) 2.8 2.4 2.30
Water consumption (cubic meters per year
per mCHF sales) 56.12 51.9 50.3
Total organic carbon (TOC) (t/year) 154 592 641
Heavy metals (kg/year) 426 545 605
Chemical waste (t/year) 27,605 31,295 38,167
General waste (t/year) 19,828 42,823 17,480

1) For the year 2009 as proposed by the Board of Directors

2) Development phases I to IV
Figures for 2007 as in Annual Report 2008
n. a. = not available
n. i. = not yet initiated